

Fernando Aranda

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6876155/fernando-aranda-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58
papers

2,965
citations

28
h-index

54
g-index

64
ext. papers

3,542
ext. citations

7.9
avg, IF

4.36
L-index

#	Paper	IF	Citations
58	Novel strategies exploiting interleukin-12 in cancer immunotherapy.. <i>Pharmacology & Therapeutics</i> , 2022 , 239, 108189	13.9	3
57	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy 2021 , 9,		3
56	Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. <i>Cancers</i> , 2021 , 13,	6.6	1
55	Firefighters for the Wrong Type of Inflammation in Tumors. <i>Cancer Discovery</i> , 2021 , 11, 2372-2374	24.4	
54	Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents. <i>Cells</i> , 2020 , 9,	7.9	5
53	Multifaceted effects of soluble human CD6 in experimental cancer models 2020 , 8,		4
52	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020 , 11, 3819	17.4	41
51	CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1074-1083	4.4	3
50	Production and use of adeno-associated virus vectors as tools for cancer immunotherapy. <i>Methods in Enzymology</i> , 2020 , 635, 185-203	1.7	2
49	Transforming growth factor beta (TGF- β) activity in immuno-oncology studies. <i>Methods in Enzymology</i> , 2020 , 636, 129-172	1.7	3
48	Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity. <i>Frontiers in Immunology</i> , 2020 , 11, 620283	8.4	0
47	Transgenic Tumor Models for Evaluating CAR T-Cell Immunotherapies. <i>Current Protocols in Pharmacology</i> , 2019 , 86, e66	4.1	
46	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN- γ <i>Journal of Immunology</i> , 2019 , 203, 696-704	5.3	4
45	Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. <i>Cell Metabolism</i> , 2019 , 30, 754-767.e9	24.6	40
44	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolimmunology</i> , 2018 , 7, e1433982	7.2	23
43	Gut microbiota metabolites for sweetening type I diabetes. <i>Cellular and Molecular Immunology</i> , 2018 , 15, 92-95	15.4	7
42	Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis. <i>Cellular and Molecular Immunology</i> , 2018 , 15, 898-906	15.4	11

41	Immune effectors responsible for the elimination of hyperploid cancer cells. <i>Oncolimmunology</i> , 2018 , 7, e1463947	7.2	9
40	Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR-B1. <i>European Journal of Immunology</i> , 2017 , 47, 1108-1118	6.1	14
39	Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	7
38	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Oncolimmunology</i> , 2017 , 6, e1373237	7.2	53
37	Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance. <i>Frontiers in Immunology</i> , 2017 , 8, 594	8.4	8
36	Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model. <i>Oncotarget</i> , 2017 , 8, 5247-5255	3.3	6
35	Immunomodulatory effects of soluble CD5 on experimental tumor models. <i>Oncotarget</i> , 2017 , 8, 108156-108169	3.9	169
34	Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function. <i>Oncolimmunology</i> , 2016 , 5, e1196309	7.2	7
33	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolimmunology</i> , 2016 , 5, e1214790	7.2	51
32	Trial Watch-Immunostimulation with cytokines in cancer therapy. <i>Oncolimmunology</i> , 2016 , 5, e1115942	7.2	35
31	Trial Watch-Oncolytic viruses and cancer therapy. <i>Oncolimmunology</i> , 2016 , 5, e1117740	7.2	76
30	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncolimmunology</i> , 2016 , 5, e1149674	7.2	41
29	Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination. <i>Oncolimmunology</i> , 2016 , 5, e1075113	7.2	14
28	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016 , 30, 147-160	24.3	285
27	Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. <i>International Journal of Cancer</i> , 2016 , 139, 1297-302	7.5	10
26	CD6 modulates thymocyte selection and peripheral T cell homeostasis. <i>Journal of Experimental Medicine</i> , 2016 , 213, 1387-97	16.6	43
25	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolimmunology</i> , 2015 , 4, e1008814	7.2	68
24	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolimmunology</i> , 2015 , 4, e1008866	7.2	162

23	Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. <i>Journal of Hepatology</i> , 2015 , 63, 329-36	13.4	18
22	Trial Watch: Adoptive cell transfer for oncological indications. <i>Onc Immunology</i> , 2015 , 4, e1046673	7.2	22
21	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Onc Immunology</i> , 2015 , 4, e1026531	7.2	22
20	Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. <i>Oncogene</i> , 2015 , 34, 3053-62	9.2	54
19	CD5 as a Target for Immune-Based Therapies. <i>Critical Reviews in Immunology</i> , 2015 , 35, 85-115	1.8	14
18	Trial Watch: Chemotherapy with immunogenic cell death inducers. <i>Onc Immunology</i> , 2014 , 3, e27878	7.2	116
17	Impact of myeloid cells on the efficacy of anticancer chemotherapy. <i>Current Opinion in Immunology</i> , 2014 , 30, 24-31	7.8	28
16	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. <i>Onc Immunology</i> , 2014 , 3, e28344	7.2	30
15	Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases. <i>PLoS ONE</i> , 2014 , 9, e96799	3.7	10
14	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
13	Trial watch: Immunostimulatory cytokines in cancer therapy. <i>Onc Immunology</i> , 2014 , 3, e29030	7.2	47
12	Consensus guidelines for the detection of immunogenic cell death. <i>Onc Immunology</i> , 2014 , 3, e955691	7.2	524
11	Trial Watch: Toll-like receptor agonists in oncological indications. <i>Onc Immunology</i> , 2014 , 3, e29179	7.2	61
10	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. <i>Onc Immunology</i> , 2014 , 3, e27048.2	7.2	64
9	Trial watch: IDO inhibitors in cancer therapy. <i>Onc Immunology</i> , 2014 , 3, e957994	7.2	166
8	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. <i>Onc Immunology</i> , 2014 , 3, e27297	7.2	86
7	Myeloid-derived cells are key targets of tumor immunotherapy. <i>Onc Immunology</i> , 2014 , 3, e28398	7.2	44
6	Trial watch: Dendritic cell-based anticancer therapy. <i>Onc Immunology</i> , 2014 , 3, e963424	7.2	54

5	Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. <i>OncolImmunology</i> , 2014 , 3, e955685	7.2	13
4	Trial Watch: Peptide vaccines in cancer therapy. <i>OncolImmunology</i> , 2013 , 2, e26621	7.2	84
3	Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. <i>Cancer Research</i> , 2011 , 71, 812-21	10.1	53
2	Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. <i>Cancer Research</i> , 2011 , 71, 3214-24	10.1	56
1	Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. <i>International Journal of Cancer</i> , 2009 , 125, 2614-23	7.5	51